Vitrolife ABOSTO:VITR +0.11%78 FCF Margin % is 21.31% as of Mar. 2026, which is 10% above its 10-year median of 19.32. GuruFocus rates OSTO:VITR with a GF Score™ of 78/100 and a GF Value™ of kr162.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Vitrolife AB ranks better than 92.02% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vitrolife AB's Free Cash Flow for the
three
months ended in Mar. 2026 was kr172 Mil. Vitrolife AB's Revenue for the
three
months ended in Mar. 2026 was kr807 Mil. Therefore, Vitrolife AB's FCF Margin % for the quarter that ended in Mar. 2026 was 21.31%.
The historical rank and industry rank for Vitrolife AB's FCF Margin % or its related term are showing as below:
OSTO:VITR'
s FCF Margin % Range Over the Past 10 Years
Min: 11.28 Med: 19.32 Max: 28.84
Current: 21.68
During the past 13 years, the highest FCF Margin % of Vitrolife AB was 28.84%. The lowest was 11.28%. And the median was 19.32%.
OSTO:VITR's FCF Margin % is ranked better than 92.02% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs OSTO:VITR: 21.68
Vitrolife AB FCF Margin % Related Terms
Vitrolife AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:VITR vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Vitrolife AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (OSTO:VITR) has a FCF Margin % of 21.31% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vitrolife AB and its competitors. This is 10% above median its historical median of 19.32. Over the past decade, Vitrolife AB's FCF Margin % has ranged from 11.28 to 28.84. According to the industry distribution chart, Vitrolife AB ranks #65 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 8%.
Is Vitrolife AB's FCF Margin % too high?
Vitrolife AB's current FCF Margin % of 21.31% is 10% above median its 10-year median of 19.32. Over the past 10 years, this metric has ranged from a low of 11.28 to a high of 28.84. Based on the distribution chart, Vitrolife AB ranks #65 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vitrolife AB has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #65 out of 815 companies for FCF Margin %. This places Vitrolife AB in the top 8% of its industry — outperforming the majority of peers. Historically, Vitrolife AB's own FCF Margin % has ranged from 11.28 to 28.84 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current FCF Margin % is 21.31%, which is 10% above median its own 10-year median of 19.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.15, compared to a current price of kr89.65 — trading 44.7% below its estimated fair value. The current FCF Margin % is 21.31%, which is 10% above median its 10-year median of 19.32. Vitrolife AB's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current FCF Margin % is 21.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr89.65 is trading 44.7% below its estimated GF Value™ of kr162.15.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for OSTO:VITR:
FCF Margin %: 21.31% (10% above median its 10-year median of 19.32)
GF Value™: kr162.15 vs. price of kr89.65 (44.7% below fair value)
No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
78GF Score
Get the complete analysis for OSTO:VITR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VITR has been successfully added to your 
